OCGN Ocugen, Inc.

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

$5.76  -0.55 (-8.72%)
As of 12/03/2021 15:59:59 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/03/2014
Outstanding shares:  199,185,877
Average volume:  20,265,113
Market cap:   $1,256,862,884
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    67577C105
ISIN:        US67577C1053
Sedol:      BK71M09
Valuation   (See tab for details)
PE ratio:   -31.26
PB ratio:   10.71
PS ratio:   0.00
Return on equity:   -44.42%
Net income %:   -422,319.68%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy